Northern Trust Corp Has $9.47 Million Stock Position in Viridian Therapeutics, Inc. $VRDN

Northern Trust Corp grew its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 1.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 702,517 shares of the company’s stock after purchasing an additional 8,375 shares during the period. Northern Trust Corp owned approximately 0.86% of Viridian Therapeutics worth $9,470,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Amalgamated Bank increased its position in shares of Viridian Therapeutics by 49.7% during the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock worth $34,000 after acquiring an additional 840 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Viridian Therapeutics by 3,892.9% during the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock worth $114,000 after acquiring an additional 8,214 shares in the last quarter. Brevan Howard Capital Management LP bought a new stake in shares of Viridian Therapeutics during the fourth quarter worth about $258,000. ProShare Advisors LLC increased its position in shares of Viridian Therapeutics by 74.1% during the fourth quarter. ProShare Advisors LLC now owns 20,584 shares of the company’s stock worth $395,000 after acquiring an additional 8,761 shares in the last quarter. Finally, Voya Investment Management LLC increased its position in shares of Viridian Therapeutics by 5.1% during the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company’s stock worth $410,000 after acquiring an additional 1,038 shares in the last quarter.

Viridian Therapeutics Trading Up 0.4%

Shares of VRDN stock opened at $18.72 on Friday. The company has a 50 day moving average of $17.37 and a 200-day moving average of $15.23. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The firm has a market cap of $1.53 billion, a P/E ratio of -4.89 and a beta of 0.53.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, hitting the consensus estimate of ($1.00). Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. During the same period last year, the firm earned ($0.81) EPS. Viridian Therapeutics’s revenue for the quarter was up 4.2% on a year-over-year basis. Sell-side analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on VRDN. Wells Fargo & Company reduced their price objective on shares of Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Jefferies Financial Group began coverage on shares of Viridian Therapeutics in a research report on Monday, August 25th. They issued a “buy” rating and a $44.00 price objective for the company. The Goldman Sachs Group upped their price objective on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Needham & Company LLC reduced their price objective on shares of Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Finally, Oppenheimer upped their price objective on shares of Viridian Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.78.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.